Sandra Black

Sunnybrook Health Sciences Centre, University of Toronto
Toronto, Canada

Phospholipase D3 Variants Double Sporadic AD Risk

RESEARCH NEWS 2013-12-13 Research News In another victory for whole-genome technology, geneticists have identified rare variants of phospholipase D3 (PLD3) that double a person’s risk for late-onset Alzheimer’s disease (LOAD). Lead author Carlos Cruchaga of Washington University

PAPER Cruchaga C, Karch CM, Jin SC, Benitez BA, Cai Y, Guerreiro R, Harari O, Norton J, Budde J, Bertelsen S, Jeng AT, Cooper B, Skorupa T, Carrell D, Levitch D, Hsu S, Choi J, Ryten M, UK Brain Expression Consortium, Hardy J, Ryten M, Trabzuni D, Weale ME, Ramasamy A, Smith C, Sassi C, Bras J, Gibbs JR, Hernandez DG, Lupton MK, Powell J, Forabosco P, Ridge PG, Corcoran CD, Tschanz JT, Norton MC, Munger RG, Schmutz C, Leary M, Demirci FY, Bamne MN, Wang X, Lopez OL, Ganguli M, Medway C, Turton J, Lord J, Braae A, Barber I, Brown K, Alzheimer’s Research UK Consortium, Passmore P, Craig D, Johnston J, McGuinness B, Todd S, Heun R, Kölsch H, Kehoe PG, Hooper NM, Vardy ER, Mann DM, Pickering-Brown S, Brown K, Kalsheker N, Lowe J, Morgan K, David Smith A, Wilcock G, Warden D, Holmes C, Pastor P, Lorenzo-Betancor O, Brkanac Z, Scott E, Topol E, Morgan K, Rogaeva E, Singleton AB, Hardy J, Kamboh MI, St George-Hyslop P, Cairns N, Morris JC, Kauwe JS, Goate AM

Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease.

Nature. 2014 Jan 23;505(7484):550-4. Epub 2013 Dec 11 PubMed: 24336208

Blocking BACE—Do Adult Mouse Phenotypes Predict Side Effects?

CONFERENCE COVERAGE 2013-12-13 Conference Coverage Despite Eli Lilly terminating development of its BACE inhibitor LY2886721 (see Jun 2013 news story), the protease remains a popular target among pharmaceutical companies looking for the next Alzheimer's disease therapy. While BACE

Sarah Martindale

London, United Kingdom

Shweta Sonawane

India

Archana S S

Deemed university
Bangalore

PAPER Martin LJ, Semenkow S, Hanaford A, Wong M

The mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Neurobiol Aging. 2014 May;35(5):1132-52. Epub 2013 Nov 16 PubMed: 24325796

PAPER Kim SH, Knight EM, Saunders EL, Cuevas AK, Popovech M, Chen LC, Gandy S

Rapid doubling of Alzheimer's amyloid-β40 and 42 levels in brains of mice exposed to a nickel nanoparticle model of air pollution.

F1000Res. 2012 Dec 21;1 PubMed: 24327847

PAPER Holland JP, Liang SH, Rotstein BH, Collier TL, Stephenson NA, Greguric I, Vasdev N

Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque.

J Labelled Comp Radiopharm. 2014 Apr;57(4):323-31. Epub 2013 Dec 11 PubMed: 24327420

PAPER Berk C, Sabbagh MN

Erratum to: Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease.

Drugs Aging. 2014 Jan;31(1):81. PubMed: 24327322

PAPER Larner AJ

Cerebral mass lesions presenting in a cognitive disorders clinic.

Br J Hosp Med (Lond). 2013 Dec;74(12):694-5. PubMed: 24326718

PAPER

Upcoming meetings related to Alzheimer's disease.

J Alzheimers Dis. 2014 Jan 1;38(4) PubMed: 24326610

PAPER Smith AD, Yaffe K

Dementia (including Alzheimer's disease) can be prevented: statement supported by international experts.

J Alzheimers Dis. 2014;38(4):699-703. PubMed: 24326609

PAPER Achouri-Rassas A, Hadj Fredj S, Mrabet Khiari H, Bibi A, Siala H, Mrabet A, Messaoud T

Association between Alzheimer disease and the-491T allele of regulatory region polymorphism of Apolipoprotein E in a Tunisian population.

Neurochem Res. 2014 Feb;39(2):244-7. Epub 2013 Dec 11 PubMed: 24326531